Tecentriq 1 200 mg concentrate for solution for infusion, Ipatasertib clinical trials

BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer

This study looks at new treatments for a specific type of breast cancer called triple-negative. It combines standard chemotherapy and Tecentriq with a new drug, Ipatasertib, to see if this combination helps shrink tumours more effectively before surgery.